top of page
  • Completed

NCT02336815 : Phase 2 - Selinexor Treatment of Refractory Myeloma (STORM)

Updated: Jun 21, 2022


Selinexor Treatment of Refractory Myeloma (STORM)


This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg plus dexamethasone 20 mg (Sd) dosed twice weekly in four-week cycles, in patients with penta-refractory MM (Parts 1 and 2) or quad refractory MM (Part 1 only).


Karyopharm Therapeutics Inc

Multiple Locations

International Study Identifier: NCT02336815

Official Title: A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab

First Posted : January 13, 2015

Click here for details on


Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information

Selinexor : National Cancer Institute

Selinexor : MedlinePlus Drug Information


Drug: Selinexor

Drug: Dexamethasone